|
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
The expressions of uPA and p38MAPK proteins were significantly higher in esophageal squamous cell carcinoma or adenocarcinoma than in normal esophageal mucosa tissue (both <i>P</i><0.0001).
|
30568465 |
2018 |
|
Adenocarcinoma
|
0.390 |
Biomarker
|
group |
BEFREE |
Finally, expression of miR-193a is inversely correlated with PLAU and K-Ras in human colon adenocarcinomas.
|
21670079 |
2011 |
|
Adenocarcinoma
|
0.390 |
Biomarker
|
group |
BEFREE |
In this study, we analyzed the role of the uPAR/uPA system in both the development and progression of pancreatic cancer in invasive ductal adenocarcinomas of the pancreas (PDA) and their premalignant precursors (PanIN lesions) in 50 patients with long-term clinical follow-up.
|
19435784 |
2009 |
|
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
We examined mRNA expression of the urokinase-type plasminogen activator (uPA), its receptor (uPAR), and the plasminogen activator inhibitor 1 (PAI-1) in a panel of adenocarcinomas of the pancreas (PC) and cancers of the papilla of Vater (CPV).
|
18376309 |
2008 |
|
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
LHGDN |
Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
|
18376307 |
2008 |
|
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
LHGDN |
We have studied the expression of urokinase-type plasminogen activator (uPA) mRNA, uPA receptor (uPAR) mRNA and immunoreactivity, and type-1 plasminogen activator inhibitor (PAI-1) mRNA and immunoreactivity in 16 prostate adenocarcinomas and 9 benign prostate hyperplasias. uPA mRNA and uPAR mRNA expression were found in 9 and 8 of the adenocarcinomas, respectively, and in 7 and 6 of the benign hyperplasias, respectively.
|
15515049 |
2005 |
|
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
We have studied the expression of urokinase-type plasminogen activator (uPA) mRNA, uPA receptor (uPAR) mRNA and immunoreactivity, and type-1 plasminogen activator inhibitor (PAI-1) mRNA and immunoreactivity in 16 prostate adenocarcinomas and 9 benign prostate hyperplasias. uPA mRNA and uPAR mRNA expression were found in 9 and 8 of the adenocarcinomas, respectively, and in 7 and 6 of the benign hyperplasias, respectively.
|
15515049 |
2005 |
|
Adenocarcinoma
|
0.390 |
Biomarker
|
group |
CTD_human |
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
|
10467400 |
1999 |
|
Adenocarcinoma
|
0.390 |
Biomarker
|
group |
BEFREE |
Using in situ hybridization to analyze the coexpression of laminin-5 and components of the plasminogen activation system, we found that the histological distribution of laminin-5-positive budding cancer cells at the invasion front in colon adenocarcinomas was identical to that of the receptor for urokinase-type plasminogen activator.
|
7664291 |
1995 |
|
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
The inhibitory effects of amiloride on uPA gene expression reported in this paper may offer the prospect of developing new therapeutic approaches to the prevention of invasion and metastasis by adenocarcinomas.
|
7750207 |
1995 |
|
Adenocarcinoma
|
0.390 |
AlteredExpression
|
group |
BEFREE |
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
|
1850957 |
1991 |